



KUWAIT ANNUAL
RADIOLOGY
CONFERENCE 2026
FROM VISION TO
PRECISION



Systematic approach of bone tumors

Leyanah Al-Mutairi

Radiology resident - KIMS



Systematic approach of Bone tumors :

Teaching Points

- A systematic approach improves accuracy in diagnosing bone tumors and guides clinical management.
- Age and location along with imaging features such as margins, matrix, periosteal reaction, and soft-tissue extension are key to narrowing the differential diagnosis.
- A structured checklist ensures consistent evaluation and reporting by Bone-RADS scoring system (Figure.8).
- Includes original illustrations to clarify and highlight the key radiologic features of common bone tumors.
- Sample case demonstrates lesion evaluation checklist.

Background

Bone tumors represent a heterogeneous group of lesions, ranging from incidental benign findings to aggressive malignancies. Accurate diagnosis requires a structured approach to improve precision, support communication, and guide management. Evaluation begins with patient age (Figure.1) and lesion location, both within the bone (epiphyseal, metaphyseal, diaphyseal; central, eccentric, cortical or juxtacortical) (Figure.2) and skeletal (axial vs. appendicular) (Figure.3). Lesion analysis includes density (Figure.4), matrix mineralization, number of lesions, and aggressiveness indicators.

Signs of aggressiveness include:

Margins (Figure.5) : Permeative or moth-eaten patterns per Lodwick classification [2] suggest malignancy.

Periosteal reaction (Figure.6) : lamellated, perpendicular, Codman triangle, or sunburst types imply rapid growth.

Endosteal scalloping and cortical destruction (Figure.8) indicate slow vs. aggressive expansion.

Pathologic fracture and soft-tissue mass suggest high-grade lesions.

A known primary malignancy raises concern for metastases.

Age

		<30	>30
B		<ul style="list-style-type: none"> Simple bone cyst Aneurysmal bone cyst Nonossifying fibroma Osteofibrous dysplasia Chondroblastoma Osteoblastoma Eosinophilic granuloma 	<ul style="list-style-type: none"> Enchondroma Giant cell tumor Paget disease
		<ul style="list-style-type: none"> Ewing sarcoma Neuroblastoma metastases Osteosarcoma 	<ul style="list-style-type: none"> Metastatic disease Multiple myeloma Lymphoma Chordoma Chondroblastoma Fibrosarcoma Malignant fibrous histiocytoma
M			

Figure 1

Location : 1) Transverse And longitudinal




Figure 2

Location : 2) Bone/Skeleton

- Bone tumor have characteristic location in the skeleton

- Those tumor on **blue** have higher frequencies in the respective location

- **EG** = Eosinophilic granuloma, **ABC** = aneurysmal bone cyst, **CS** = chondrosarcoma, **FD** = fibrous dysplasia, **GCT** = giant cell tumor, **MM** = multiple myeloma, **NOF** = nonossifying fibroma, **SBC** = simple bone cyst, **OO** = osteoid osteoma.

- **Osteosarcoma**, Ewing sarcoma, **Chondroblastoma**, **NOF**, **ABC**, **SBC**, **GCT**, **Osteochondroma**









Figure 3

Density			
Sclerotic	Lytic		Mixed
	Well-defined	Ill-defined	
Stress fracture/Insufficiency fracture Bone infarct Chronic Osteomyelitis Osteoma Osteoid osteoma Healed nonossifying fibroma Osteoblastic metastatic carcinoma Paget disease Bone island (enostosis)	Fibrous dysplasia Enchondroma and Eosinophilic granuloma Giant cell tumor and Geode osteoblastoma Metastases and Myeloma Aneurysmal bone cyst Simple bone cyst Hyperparathyroidism (bone tumor) and Hemangioma Infection (Osteomyelitis) and Infarction Chondroblastoma and Chondromyxoid fibroma	Esoinophilic granuloma Giant cell tumor Osteomyelitis Multiple myeloma Metastases Ewing sarcoma Osteosarcoma Chondrosarcoma Leukemia/Lymphoma	Paget disease Metastases Fibrous dysplasia Adamantinoma Early bone infarct
	FEGNOMASHIC		

Figure 4

Lodwick Classification	Type I (geographic)			Type II (Moth-eaten)	Type III (Permeative)
	Type IA	Type IB	Type IC		
					

Modified L-M system	Grade IA	Grade IB	Grade II	Grade IIIA	Grade IIIB	Grade IIIC
	Geographic, well defined lesion with a sclerotic rim	Geographic, well defined without sclerotic rim	Geographic, ill-defined with a wide zone of transition	Changing margin or progressive endosteal scalloping at surveillance	Non-geographic moth-eaten or permeative	Radiographically occult

Figure 5

Periosteal reaction

Nonaggressive periosteal reaction		Agressive periosteal reaction		Found In
Thin		Lamellated (onion skin)		Sarcomas, Osteomyelitis, Chondroblastoma
Solid		Perpendicular (hair-on-end)		Typically Ewing sarcoma, can present in Osteosarcomas
Thick irregular		Divergent (sunburst)		Osteosarcomas
Separated		Codman triangle		Commonly osteosarcomas, occasionally infection and mets

Figure 6

Cortical involvement

Endosteal scalloping	Expansile remodeling/cortical insufflation (Ballooning)	Cortical destruction
Erosion of the inner surface of the cortex	The bone has time to produce new periosteum as the inner surface is being eroded, resulting in expansion	Seen in high grade malignant and aggressive lesions

Figure 7

Structured Report and Management (ACR Bone-RADS™ v2023)


		ACR Bone-RADS™ Score	Management										
Margins	IA = 1 IB = 3 II = 5 IIIA-C = 7	<table border="1"> <tr> <td style="background-color: #cccccc;">0 Incompletely Characterized Point Total = N/A</td> <td> <ul style="list-style-type: none"> Further workup is necessary Additional radiographic views or cross-sectional imaging for further evaluation </td> </tr> <tr> <td style="background-color: #90ee90;">1 Very Low Risk Point Total = 1-2</td> <td> <ul style="list-style-type: none"> If asymptomatic, consider workup to be complete vs annual surveillance to ensure expected stability If symptomatic or change in clinical presentation, consider advanced imaging and orthopedic oncology referral for treatment of benign tumor </td> </tr> <tr> <td style="background-color: #ffff00;">2 Low Risk Point Total = 3-4</td> <td> <ul style="list-style-type: none"> Short interval (3-6 month) surveillance to ensure stability Consider advanced imaging to assess tumor composition and possibly biopsy to confirm benignity if needed Consider orthopedic oncology referral for surveillance or treatment of benign tumor </td> </tr> <tr> <td style="background-color: #ffa500;">3 Intermediate Risk Point Total = 5-6</td> <td> <ul style="list-style-type: none"> Orthopedic oncology referral for probable biopsy and treatment planning Recommend advanced imaging such as CT, MRI, or bone scan for further characterization </td> </tr> <tr> <td style="background-color: #ff0000;">4 High Risk Point Total ≥ 7</td> <td> <ul style="list-style-type: none"> Orthopedic oncology referral for recommended biopsy and treatment planning Advanced imaging for tumor staging including additional sites of disease </td> </tr> </table>	0 Incompletely Characterized Point Total = N/A	<ul style="list-style-type: none"> Further workup is necessary Additional radiographic views or cross-sectional imaging for further evaluation 	1 Very Low Risk Point Total = 1-2	<ul style="list-style-type: none"> If asymptomatic, consider workup to be complete vs annual surveillance to ensure expected stability If symptomatic or change in clinical presentation, consider advanced imaging and orthopedic oncology referral for treatment of benign tumor 	2 Low Risk Point Total = 3-4	<ul style="list-style-type: none"> Short interval (3-6 month) surveillance to ensure stability Consider advanced imaging to assess tumor composition and possibly biopsy to confirm benignity if needed Consider orthopedic oncology referral for surveillance or treatment of benign tumor 	3 Intermediate Risk Point Total = 5-6	<ul style="list-style-type: none"> Orthopedic oncology referral for probable biopsy and treatment planning Recommend advanced imaging such as CT, MRI, or bone scan for further characterization 	4 High Risk Point Total ≥ 7	<ul style="list-style-type: none"> Orthopedic oncology referral for recommended biopsy and treatment planning Advanced imaging for tumor staging including additional sites of disease 	
0 Incompletely Characterized Point Total = N/A	<ul style="list-style-type: none"> Further workup is necessary Additional radiographic views or cross-sectional imaging for further evaluation 												
1 Very Low Risk Point Total = 1-2	<ul style="list-style-type: none"> If asymptomatic, consider workup to be complete vs annual surveillance to ensure expected stability If symptomatic or change in clinical presentation, consider advanced imaging and orthopedic oncology referral for treatment of benign tumor 												
2 Low Risk Point Total = 3-4	<ul style="list-style-type: none"> Short interval (3-6 month) surveillance to ensure stability Consider advanced imaging to assess tumor composition and possibly biopsy to confirm benignity if needed Consider orthopedic oncology referral for surveillance or treatment of benign tumor 												
3 Intermediate Risk Point Total = 5-6	<ul style="list-style-type: none"> Orthopedic oncology referral for probable biopsy and treatment planning Recommend advanced imaging such as CT, MRI, or bone scan for further characterization 												
4 High Risk Point Total ≥ 7	<ul style="list-style-type: none"> Orthopedic oncology referral for recommended biopsy and treatment planning Advanced imaging for tumor staging including additional sites of disease 												
Periosteal reaction	None = 0 Non-aggressive = 2 Aggressive = 4												
Endosteal erosion	Mild = 0 Moderate = 1 Deep = 2												
Pathological fracture	If yes = 2												
Soft tissue mass	If yes = 4												
Know primary cancer	If yes = 2												

ACR Bone-RADS™ score, assessment categories and management. American College of Radiology Committee on Bone-RADS™. Bone-RADS™ v2023 Assessment Categories and Scoring System. Available at: <https://www.acr.org/-/media/ACR/Files/RADS/Bone-RADS/Bone-RADS-v2023-Assessment-Categories-Table-Final.pdf>. (Reprinted with permission from the ACR.)

Figure 8

Sample case

► AP radiograph of a 14 year old boy with right knee pain.



Checklist		Points
Patient age	<30	-
Location (skeleton)	Distal femur	-
Location (transverse)	Eccentric	-
Location (longitudinal)	Diaphyseal-metaphyseal	-
Density	Lytic	-
Mineralization	None	-
Margins	Lodwick IA, Modified Lodwick-Madewell IA	+ 1
Number	Single	-
Periosteal reaction	None	+ 0
Cortical involvement	Moderate endosteal scalloping (►) Expansile remodeling	+ 1
Pathologic fracture	None	+ 0
Soft-tissue mass	No	+ 0
Other	Open growth plates (►)	-
Total		2

ACR Bone-RADS™ Score	Management
1 Very Low Risk	<ul style="list-style-type: none"> • If asymptomatic, consider workup vs annual surveillance • If symptomatic or change in clinical presentation, consider advanced imaging and orthopedic oncology referral

Differential diagnosis
<ul style="list-style-type: none"> • Giant cell tumor • Aneurismal bone cyst • Nonossifying fibroma • Chondromyxoid fibroma • Fibrous dysplasia

Final diagnosis
Nonossifying fibroma (NOF)

- References:

- González-Huete A, Salgado-Parente A, Suevos-Ballesteros C, et al. Radiographic evaluation of bone tumors. *RadioGraphics*. 2023;43(11):e230048.
- Benndorf M, Bamberg F, Jungmann PM. The Lodwick classification for grading growth rate of lytic bone tumors: a decision tree approach. *Skeletal Radiol*. 2022;51(4):737–745.
- American College of Radiology. Bone-RADS v2023: Assessment Categories and Scoring System. Reston, VA: ACR; 2023. Available from: <https://www.acr.org/-/media/ACR/Files/RADS/Bone-RADS/Bone-RADS-v2023-Assessment-Categories.pdf>